C4 Therapeutics, Inc. · NASDAQ:CCCC
C4 Therapeutics — Investor Presentation (May 2025)
26 slides from C4 Therapeutics's investor presentation, May 2025
Slide 1: Protein degraded. Disease targeted. Lives transformed.
Protein degraded. Disease targeted. Lives transformed. May 2025
Slide 2: Forward-looking Statements and Intellectual Property
Forward-looking Statements and Intellectual Property FORWARD-LOOKING STATEMENTS The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,”
Slide 3: Our Mission
Our portfolio of degrader medicines pursues targets that may benefit from a degrader approach: Our Mission To deliver on the promise of Cemsidomide CFT19461 targeted protein degradation targeting IKZF1/3 for targeting BRAF V600 mutant for science to create a new multiple myeloma and solid tumors inc
Slide 4: C4T Has Been at the Forefront of TPD Science and Is On the Path to Becoming a Fully Integrated Biotechnology Company
C4T Has Been at the Forefront of TPD Science and Is On the Path to Becoming a Fully Integrated Biotechnology Company Leading the Way in Designing Demonstrating Delivering on the Promise of Orally Bioavailable Degraders Proof of Concept Targeted Protein Degradation 2015 – 2020 2020 – 2025 2025 and be
Slide 5: Focused Pipeline to Advance a Portfolio of Degrader Medicines Targeting Areas of High Unmet Need
Focused Pipeline to Advance a Portfolio of Degrader Medicines Targeting Areas of High Unmet Need EARLY LATE PROGRAM TARGET INDICATIONS RESEARCH PRECLINICAL DEVELOPMENT DEVELOPMENT RIGHTS MM Multiple Myeloma & Cemsidomide IKZF1/3 Non-Hodgkin’s Lymphoma NHL CFT89191 EGFR L858R Non-Small Cell Lung Canc
Slide 6: Prioritized Portfolio with Multiple 2025 Milestones
Prioritized Portfolio with Multiple 2025 Milestones 2Q 2025: Completed Phase 1 dose escalation in MM 3Q 2025: Present data from completed Phase 1 dose escalation in MM Cemsidomide 4Q 2025: Complete Phase 1 dose escalation in NHL and present data IKZF1/3 2H 2025: Open expansion cohort(s) in PTCL in t
Slide 7: Advancing Oncology and Non-oncology Discovery Programs with Collaboration Partners
Advancing Oncology and Non-oncology Discovery Programs with Collaboration Partners Evaluating targets in autoimmune diseases & Discovering targeted Discovering and Delivered two oncology protein degraders developing degrader development candidates against critical antibody conjugates in for non-onco
Slide 8: Cemsidomide
Cemsidomide IKZF1/3 Degrader Multiple Myeloma & Non-Hodgkin’s Lymphoma
Slide 9: IKZF1/3 Are Key Promoters of Myeloma and Lymphoma Cell Survival
Multiple Myeloma IKZF1/3 Are Key Promoters of Myeloma and Lymphoma Cell Survival and Will Remain Important Therapeutic Targets for These Indications Hematopoietic Stem Cell Key Roles of IKZF1/3: • Multiple myeloma and lymphoma cells rely on IKZF1/3 and IRF4 for survival IKZF1/3 Common Myeloid Common
Slide 10: Cemsidomide Dose Escalation Is Complete With 100 µg QD Dose Level Declared Safe
Multiple Myeloma Cemsidomide Dose Escalation Is Complete With 100 µg QD Dose Level Declared Safe; Patients Enrolling in the Expansion Cohort at this Dose Level KEY INCLUSION CRITERIA DOSE ESCALATION • Adults with MM, R/R to at least 3 prior CEMSIDOMIDE 14/14 + DEX* lines of therapy that have include
Slide 11: Clinical Evidence of Immune T-cell Activation With Cemsidomide Monotherapy
Multiple Myeloma Clinical Evidence of Immune T-cell Activation With Cemsidomide Monotherapy Supports potential of cemsidomide % positive cells (C1D21 vs C1D1) as a maintenance therapy option 100 C1D1 **** C1D21 and in combination with other MM agents to improve efficacy: 80 ** ✓ Cemsidomide induces
Slide 12: Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Potential Best-in-Class Profile
Multiple Myeloma Updated Cemsidomide Multiple Myeloma Data Further Demonstrate its Potential to Have a Best-in-Class Profile Cemsidomide continued to be well-tolerated with manageable neutropenia1 Compelling anti-myeloma activity observed across multiple doses1 Cemsidomide +Dex - Overall Response Ra
Slide 13: Cemsidomide Has the Potential to Become a Treatment Option Across Lines of Therapy
Multiple Myeloma Cemsidomide Has the Potential to Become a Treatment Option Across Lines of Therapy and Address a Growing Relapsed Refractory Patient Population INITIAL CEMSIDOMIDE DEVELOPMENT PATH IN MM U.S. + EU4 + UK Addressable Patients (2024)1 ~65,000 ~56,000 ~49,000 ~42,000 ≥23,000 Treatment L
Slide 14: Cemsidomide Positioned to Be an IKZF1/3 Degrader of Choice Across Various Combinations
Multiple Myeloma With a Potential Best-in-Class Profile, Cemsidomide Is Positioned to Be an IKZF1/3 Degrader of Choice Across Various Combinations EVOLVING MULTIPLE MYELOMA TREATMENT LANDSCAPE U.S. + EU4 + UK Addressable ~65,000 ~56,000 ~49,000 ~42,000 ≥23,000 Patients (2024) Treatment Line 1L 2L 3L
Slide 15: Cemsidomide Phase 1 Dose Escalation Trial in NHL Continues to Progress
NHL Cemsidomide Phase 1 Dose Escalation Trial in NHL Continues to Progress KEY INCLUSION CRITERIA DOSE ESCALATION • Adults with NHL, R/R to prior therapy CEMSIDOMIDE 14/14 Utilizing a Bayesian logistic regression model until • PTCL patients must have received determination of the MTD and/or RP2D at
Slide 16: Cemsidomide Was Well-tolerated With Manageable Incidents of On-target Neutropenia
NHL Cemsidomide Was Well-tolerated With Manageable Incidents of On- target Neutropenia Common (>20% All Grades) TEAEs and All Grade Grade 3 Grade 4 Events of Interest*, n (%) (N=23) (N=23) (N=23) Infections 15 (65) 4 (17) 2 (9) Upper respiratory tract infection 4 (17) 0 0 • 2 DLTs occurred at 100 µg
Slide 17: Compelling and Deep Responses Achieved Across PTCL Subtypes
NHL Compelling and Deep Responses Achieved Across PTCL Subtypes PET-CT–based Assessment of PMR or Better by PTCL Subtype* (N=16) ORR 100% 100% CMR • Cemsidomide PMR monotherapy 75% produced Best Response % (N) 75% (3) responses in all ORR 50% four PTCL subtypes 50% ORR 44% • All AITL patients (4/4)
Slide 18: Cemsidomide NHL Data Supports Further Development in PTCL
NHL Cemsidomide NHL Data Supports Further Development in PTCL, Which Provides the Fastest Path to Market INITIAL CEMSIDOMIDE DEVELOPMENT PATH IN PTCL U.S. + EU4 + UK Addressable Patients (2024)1 ~16,000 ≤12,000 Treatment Line 1L 2L+ Study Currently Phase 2 (Single Arm) Being Enabled Cemsidomide Mono
Slide 19: Cemsidomide Has a Strategic Path to Become a Potential Backbone Therapy for MM and NHL
Cemsidomide Has a Strategic Path to Become a Potential Backbone Therapy for MM and NHL Across Various Lines of Treatment 1 2 3 • Highest unmet patient • Combination strategies • Maximize broad need opportunities in a with other MM agents to applicability growing population expand to 2L+ MM • Drive r
Slide 20: CFT8919
CFT8919 EGFR L858R Degrader Non-Small Cell Lung Cancer
Slide 21: CFT8919 Is a Potent, Oral, Allosteric, Mutant-selective Degrader of EGFR L858R
CFT8919 Is a Potent, Oral, Allosteric, Mutant-selective Degrader of EGFR L858R With Potential to Improve Outcomes for NSCLC Patients Current Approved EGFR Inhibitors Have Limitations: • Patients become refractory due to secondary mutations • NSCLC patients with L858R have inferior clinical CFT8919 o
Slide 22: CFT8919 Binds to Allosteric Site, Avoiding Impact of L858R Non-classical Co-mutations
CFT8919 Binds to Allosteric Site, Avoiding Impact of L858R Non-classical Co-mutations in the Orthosteric Binding Pocket 2 EGFR-L858R Tumors More Frequently Patients with L858R Do Less Well on Co-express Non-classical EGFR 1 Osimertinib Therapy vs Ex19del Mutations Before Exposure to EGFR TKI1 CFT891
Slide 23: CFT8919 Is Selective for EGFR L858R and Active in Osimertinib Resistance in Preclinical Models
CFT8919 Is Selective for EGFR L858R and Active in a Setting of Osimertinib Resistance in Preclinical Models Specific for EGFR Exon 21 Mutants Active in Setting of EGFR C797S Vehicle PO BID BaF3 EGFRL858R/T790M/C797S 2000 Osimertinib 25 mpk PO QD Tumor volume (mm3) CFT8919 10 mpk PO BID EGFR-L861Q CF
Slide 24: CFT8919 Demonstrates Activity in Brain Metastasis Model
CFT8919 Demonstrates Activity in Brain Metastasis Model Mean Plasma & Tumor In vivo Efficacy In vivo Body Weight Change Concentration in plasma (ng/ml) and tumor (ng/g) 600 20 10000 Vehicle Body Weight Change (%) CFT8919 concentration BLI (photons/s×106) CFT8919 (50mg/kg PO BID) 10 Mean plasma Mean
Slide 25: CFT8919 Has the Potential to Address Multiple Opportunities with High Unmet Needs
CFT8919 Has the Potential to Address Multiple Opportunities with High Unmet Needs CFT8919’s Fastest Path to Market Is in 2L+ With Potential to Expand Into Front-Line 2024 Annual Incidence of EGFR 2L+ Front-line L858R Mutated NSCLC1: Development Rationale: Development Rationale: • U.S.: ~17,000 • Fas
Slide 26: Prioritized Portfolio with Multiple 2025 Milestones
Prioritized Portfolio with Multiple 2025 Milestones 2Q 2025: Completed Phase 1 dose escalation in MM 3Q 2025: Present data from completed Phase 1 dose escalation in MM Cemsidomide 4Q 2025: Complete Phase 1 dose escalation in NHL and present data IKZF1/3 2H 2025: Open expansion cohort(s) in PTCL in t